Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.

EMERYVILLE, Calif., May 14, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company’s supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant),…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks